Revance Therapeutics Inc

Revance Therapeutics Inc

  • Price (USD)30.07
  • Today's Change0.14 / 0.47%
  • Shares traded321.52k
  • 1 Year change+38.00%
  • Beta1.2466
Data delayed at least 15 minutes, as of Jun 16 2021 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications: cervical dystonia, adult upper limb spasticity and plantar fasciitis. It has a portfolio of products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription and loyalty digital services.

  • Revenue in USD (TTM)28.57m
  • Net income in USD-291.80m
  • Incorporated1999
  • Employees470.00
  • Location
    Revance Therapeutics Inc1222 Demonbreun Street, Suite 1001NASHVILLE 37203United StatesUSA
  • Phone+1 (510) 742-3400
  • Fax+1 (302) 674-5266
  • Websitehttp://www.revance.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Atea Pharmaceuticals Inc114.62m23.75m1.95bn42.0093.103.3382.0517.020.25330.25331.387.090.267----2,938,923.005.53--7.89------20.72------0.00------22.00------
Organogenesis Holdings Inc379.12m44.21m2.02bn910.0043.9712.8638.785.340.35910.35913.171.231.443.357.24416,613.2016.76-7.7522.18-9.0475.20--11.66-11.312.104.990.3485--29.63--143.67------
Ligand Pharmaceuticals Inc.208.41m39.25m2.06bn155.0053.502.7627.839.892.312.3112.6144.790.1681.534.441,344,568.003.1616.383.3219.2083.7492.7018.83100.574.18--0.3242--54.9820.99-100.47--1.57--
USANA Health Sciences, Inc.1.18bn128.73m2.08bn1.94k16.875.2114.611.776.096.0955.6219.722.222.98--605,250.1024.3320.9832.9128.9681.2382.4010.9510.011.89--
Deciphera Pharmaceuticals Inc67.18m-254.98m2.08bn350.00--4.13--30.96-4.49-4.491.188.690.1012----191,945.70-38.40-41.47-41.82-45.5799.33---379.54-946.278.46--0.00--68.35---38.61--106.38--
Revance Therapeutics Inc28.57m-291.80m2.14bn470.00--8.75--74.94-4.77-4.770.46683.420.045----60,778.72-45.99-50.74-49.61-56.1268.54---1,021.48-3,963.977.88-24.060.5338--3,610.65119.61-76.94--4.84--
Xencor Inc124.27m-63.75m2.16bn202.00--3.70--17.35-1.11-1.112.1610.020.1828--7.80615,217.80-9.38-3.44-10.68-4.05-----51.29-18.23----0.00---21.7034.61-357.98--30.23--
Kymera Therapeutics Inc-100.00bn-100.00bn2.20bn92.00--7.96----------6.13----------------------------0.0041--1,059.99---32.48------
Hims & Hers Health Inc52.31m-55.79m2.21bn181.00--7.90--42.32-0.51-0.510.91561.530.1895----289,027.60-20.21---21.00--76.93---106.64--17.06--0.00-------365.76------
bluebird bio Inc241.67m-621.89m2.21bn1.21k--1.84--9.16-9.38-9.383.7217.800.1526--201.39199,229.20-39.28-31.85-44.81-34.5897.25---257.34-681.645.23-30.820.00--461.2577.8821.65--32.66--
Zentalis Pharmaceuticals Inc0.00-151.62m2.26bn124.00--8.37-----3.84-3.840.006.540.00----0.00-73.44---91.12--------------0.00-------158.07------
Rubius Therapeutics Inc0.00-161.58m2.28bn231.00--7.57-----1.99-1.990.003.370.00----0.00-41.51---44.85-------------37.640.2008-------2.61------
Morphic Holding Inc42.62m-49.54m2.29bn89.00--6.20--53.83-1.56-1.561.3410.210.1238--13.23478,831.50-14.39---16.04-------116.24------0.00--164.74---3.86------
Prothena Corporation PLC872.00k-124.31m2.30bn66.00--9.79--2,632.82-3.11-3.110.02185.310.0022--9.9713,212.12-31.91-29.47-33.66-31.37-----14,255.73-2,109.92----0.00--4.79-11.90-43.08---32.34--
Myriad Genetics, Inc.566.10m-168.70m2.31bn2.70k--2.63--4.08-2.25-1.977.5411.410.40676.445.76209,666.70-12.13---13.39--68.49---29.82--2.04-19.310.1496--------------
ALX Oncology Holdings Inc527.00k-57.69m2.33bn24.00--5.55--4,413.07-2.04-2.040.015910.410.002----22,913.04-20.13---20.82--9.11---10,336.05-----87.860.0005---75.35---118.91------
Data as of Jun 16 2021. Currency figures normalised to Revance Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

45.90%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 20214.83m6.75%
GIC Pte Ltd. (Investment Management)as of 31 Dec 20203.83m5.36%
The Vanguard Group, Inc.as of 31 Mar 20213.37m4.71%
AllianceBernstein LPas of 31 Mar 20213.35m4.69%
Palo Alto Investors LPas of 31 Mar 20213.20m4.48%
ArrowMark Colorado Holdings LLCas of 31 Mar 20213.16m4.42%
JPMorgan Investment Management, Inc.as of 31 Mar 20212.90m4.06%
Wellington Management Co. LLPas of 31 Mar 20212.84m3.96%
Fidelity Management & Research Co. LLCas of 31 Mar 20212.78m3.88%
Capital Research & Management Co. (World Investors)as of 31 Mar 20212.57m3.59%
More ▼
Data from 31 Mar 2021 - 10 Jun 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.